01—Abstract
Summary
Summary of the 10-K filed February 27, 2025. Cited figures are marked; the original filing is the authoritative source.
Pfizer Inc.'s 2024 Form 10-K highlights a year of revenue growth driven by key products like Paxlovid, the Seagen acquisition, and strong performance from the Vyndaqel family and Eliquis, despite a decline in Comirnaty revenues.
Total revenues reached $63.6 billiona, a 7% increase year-over-year, with operational growth contributing significantly. The company is strategically focused on improving R&D productivity, expanding margins, achieving commercial excellence, and optimizing capital allocation in 2025.
Pfizer continues to navigate a complex regulatory and competitive landscape, including ongoing discussions around drug pricing, patent expirations for key products, and the integration of the Seagen acquisition, which is expected to generate significant synergies. Investors should note the potential impact of upcoming patent expiries between 2026 and 2030 on revenue streams, alongside ongoing efforts to bolster its product pipeline through internal development and strategic business development.
02—Key points
Key Highlights
- Total revenues increased by 7% to $63.6 billion in 2024, driven by Paxlovid, the Seagen acquisition, Vyndaqel family, and Eliquis, partially offset by a decline in Comirnaty.
- The company is focused on four key priorities for 2025: improving R&D productivity, expanding margins, achieving commercial excellence, and optimizing capital allocation.
- Significant revenue declines were noted for Comirnaty (-53% operationally) and Paxlovid (-57% operationally), reflecting the transition from government contracts to commercial markets and fluctuating demand.
- The acquisition of Seagen in December 2023 is a major strategic move, expected to strengthen Pfizer's oncology portfolio and generate significant cost synergies.
- Pfizer is actively managing the impact of upcoming patent expirations, with a moderate impact expected in 2025 and a more significant impact anticipated between 2026 and 2030.
- The company acknowledges the ongoing pricing pressures from payors and governments, particularly in relation to the Inflation Reduction Act (IRA), which is expected to have a net unfavorable impact on revenue of approximately $1 billion in 2025.
- Pfizer continues to invest in its R&D pipeline, with a focus on oncology, internal medicine, vaccines, and inflammation & immunology, and has undertaken organizational changes to consolidate its R&D operations.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2024filed February 27, 2025Financial Statements
FY2024 against FY2023
| Line item | FY2024FY2023 | Change |
|---|---|---|
| Revenue | $63.63B$59.55B | +6.8% |
| Cost of Revenue | $17.85B$24.95B | −28.5% |
| Gross Profit | $45.78B$34.60B | +32.3% |
| SG&A Expenses | $14.73B$14.77B | −0.3% |
| Interest Expense | $3.09B$2.21B | +39.9% |
| Net Income | $8.03B$2.12B | +279.0% |
| EPS (Basic) | $1.42$0.38 | +273.7% |
| EPS (Diluted) | $1.41$0.37 | +281.1% |
| Shares Outstanding (Basic) | 5.66B5.64B | +0.4% |
| Shares Outstanding (Diluted) | 5.70B5.71B | −0.2% |
05—Questions
Frequently Asked Questions
What were Pfizer's key financial drivers in 2024?
Pfizer's total revenues grew by 7% to $63.6 billion in 2024. This growth was primarily driven by Paxlovid, the addition of Seagen's revenues following its acquisition in December 2023, and strong performance from the Vyndaqel family and Eliquis. These positive contributions were partially offset by a significant decline in Comirnaty revenues.
What are Pfizer's strategic priorities for 2025?
For 2025, Pfizer's key strategic priorities are: 1. Improving R&D productivity with a sharpened focus. 2. Expanding margins and maximizing operational efficiency. 3. Achieving commercial excellence in its key categories. 4. Optimizing capital allocation.
What is the impact of upcoming patent expirations on Pfizer's business?
Pfizer anticipates a moderate impact from patent expirations on its revenues in 2025, with a more significant impact expected between 2026 and 2030 as several of its in-line products experience these expirations. The company is actively working to defend its patent rights and manage this transition.
How is the Inflation Reduction Act (IRA) expected to affect Pfizer?
Pfizer expects the Inflation Reduction Act (IRA), particularly the changes to Medicare Part D benefit design, to have a net unfavorable impact on revenue of approximately $1 billion in 2025. This is due to factors like the sunsetting of the Coverage Gap Discount Program and the addition of new manufacturer discounts, which more than offset anticipated benefits from the out-of-pocket cap and prescription payment plan.
What is the significance of the Seagen acquisition?
The acquisition of Seagen in December 2023 for $43.4 billion (net of cash acquired) is a significant strategic move that is expected to bolster Pfizer's oncology portfolio, particularly in antibody-drug conjugate (ADC) technology. The company anticipates generating approximately $1 billion in annual cost synergies from this integration by 2026.
06—Continue